Abstract: Described are water-dispersible or water-soluble polymer films incorporating at least one cosmetic or dermatologic active agent and a method for the production thereof. The active agents involved are particularly anti-cellulite agents, moisturizers, anti-wrinkle agents and skin smoothing agents.

Abstract: A pharmaceutical composition comprising a pharmaceutically active agent, a core, a coating comprising an inner film comprising cellulose acetate and hydroxypropylmethylcellulose in a ratio of cellulose acetate:hydroxypropylmethylcellulose of 80% to 99.5%:0.5% to 20% and an outer film comprising ethylcellulose and hydroxypropylcellulose in a ratio of ethylcellulose:hydroxypropylcellulose of 50% to 80%:20% to 50%.

Abstract: Novel materials for controlling molluscs, such as snails and slugs, using carbohydrates including celluloses, hemicellulose complexes, and/or lignin, for inducing death in molluscs. The materials are non-toxic, will not contaminate a drinking water supply, will not harm fish, birds or wild life, will not cause any harmful effects if swallowed or absorbed through the skin, will not harm children or pets, and can be safely eaten by domestic animals and livestock that may consume such dead molluscs. The materials may be applied in various formulations at various water contents. The materials do not provide nutrition to the molluscs, and disrupt normal bodily functions resulting in death. An attractant may be included to encourage ingestion by the molluscs.

Abstract: The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a pH-independent material in combination.

Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Abstract: A process for producing a tablet characterized by performing high-speed direct compression with a moving speed of a pestle of 800 mm/s or more while compressing a powder which contains at least 15 to 80% by mass of cellulose, an active ingredient and a lubricant and has an angle of repose of 50° C. or less, a compression degree of 20% or more and an elongation at break of 30 ?m or more.

Abstract: The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed within the gel.

Abstract: The present disclosure generally relates to a formulation. More particularly, the formulation may be applied to skin and/or used in combination with a personal care product to improve absorbance and leakage control of the personal care product, and to promote a more positive feel and comfort through improved skin cleanliness and health.

Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.

Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes, especially mucositis.

Abstract: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions comprise a combination of an oxidized regenerated cellulose component and a non-steroidal anti-inflammatory drug (NSAID) which functions as an inhibitor of cyclooxygenase enzyme (Cox) activity. Such methods comprise administering an effective amount of the composition directly to the serosal surfaces of the gastrointestinal and other visceral organs.

Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.

Abstract: The present invention provides new nanoparticles and microparticles of hydrophilic character, prepared out of a cationic chitosan derivative and a polyanionic polymer.

Abstract: A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an amount of less than 15% by weight a glidant and a lubricant,

Abstract: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.

Abstract: A delivery system and method for delivering soluble dietary fibers in a chewable tablet form which is palatable and demonstrates a high degree of consumer acceptability.

Abstract: Described herein are implantable medical devices comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue. The triggerable bioadhesive property of the polymer can be triggered or activated by exposure to a stimulus. Also, the present invention pertains to methods of making an implantable medical device comprising a biocompatible polymer comprising a triggerable bioadhesive property that allows the device to adhere to body tissue.

Abstract: The disclosure provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions include an article containing cellulose, e.g., cotton gauze, and a cross-linked polysaccharide ionically linked to the cellulose. Methods of making and using the hemostatic compositions are also provided.

Abstract: Bioadhesive films for delivery of active agent to the mucosa are disclosed. Particularly, bioadhesive films for treating the vaginal mucosa are disclosed.

Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.

Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

Abstract: Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module. In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a three piece capsule, a capsule-in-a-capsule or a tablet-in-a-capsule, and the primary and secondary modules are interchangeable.

Abstract: Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Abstract: Aspects of the invention include a sustained release dosage form that can be administered to an oral cavity, e.g., the mouth. In certain embodiments, the sustained release dosage form is formulated as a lozenge or gum that may be administered to an oral cavity for the purpose of providing lubrication therein. In certain embodiments, the sustained release dosage form not only provides lubrication to a mucosal surface of an oral cavity, but also provides for the sustained release of a flavoring and/or beneficial agent. Accordingly, in certain embodiments, the sustained release dosage form includes a water-insoluble polymer, e.g., ethylcellulose, an essential oil component, and an effective amount of a film forming binder, e.g., xanthan gum.

Abstract: Orally deliverable pharmaceutical compositions are provided comprising a drug of tow water solubility suspended in an aqueous liquid vehicle comprising a wetting agent, a thixotropic thickening agent, and an inorganic suspending agent. The compositions are thixotropic, substantially deflocculated, and substantially physically stable.

Abstract: A suspendible enteric coating composition for encasing orally ingestible articles wherein the enteric coating composition comprises a pH-dependent polymer selected from a group containing alginates and alginic acids, a pH-independent water insoluble polymer selected from the group comprising ethylcellulose and ethylcellulose-containing compositions, and a plasticizer selected from the group containing triethyl citrate, glycerin, propylene glycol, triacetin, acetylated monoglycerides, dibutyl sebacate, polyethylene glycols, sorbitals, middle chain triglycerides and combinations thereof.

Abstract: Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers, either natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties (such as solubility or degradation rates according to a specific environment, for example) of such films. The water soluble films may be processed into capsules, packets or other containers.

Abstract: The present invention provides an intraoral rapid-disintegrating pharmaceutical composition which exhibits excellent intraoral disintegrating property and high hardness, and which can be applied, in particular, to a pharmaceutically active ingredient which is unstable in water. The pharmaceutical composition, which contains lactose and powdered cellulose, exhibits high hardness without prolongation of its intraoral disintegration time. When a disintegrating agent is further incorporated into the pharmaceutical composition, the hardness of the composition is increased without prolongation of its intraoral disintegration time. When magnesium aluminometasilicate, and one or more species selected from among silicic acid and silicic acid salts other than magnesium aluminometasilicate are further incorporated into the pharmaceutical composition, the composition exhibits higher hardness without prolongation of its intraoral disintegration time.

Abstract: A method for embolization using liquid embolic materials is described. The method comprises the use of two liquid components. The first liquid component is an aqueous solution or dispersion comprising at least one oxidized polysaccharide. The second liquid component is either an aqueous solution or dispersion comprising at least one water-dispersible, multi-arm amine, or a water-dispersible multi-arm amine in the form of a neat liquid. The two components crosslink in situ to form a hydrogel that should act as an effective embolic agent.

Abstract: A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary solid dosage, and prepared for oral administration before bedtime. Usually, structure is configured to initially release a calmative or other sleep-compatible substance by prompt dissolution. The initial release is followed by a specific period of delay, which in basic formulations entails no release of any drug, and which allows a nominal interval of sleep. At the terminus of the delay, a final agent is released to induce wakeup. Incorporation of agents of opposite action within a unitary dosage form renders utility which is uniquely appropriate to the invention. In a preferred embodiment, delay of release and final delivery of wakeup agent are arranged by a dialysis membrane which eventually bursts as a result of osmotic pressure generated by a hydrophilic core.

Abstract: The present invention provides a drug delivery system by noninvasive administration, which is excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue. By administering a solid composition comprising a drug and a mucoadhesive substance having an adhesion strength of from 200 to 1000 g in the conjunctival sac, a drug delivery system excellent in drug transfer to a tissue of the posterior segment of the eye via a local eye tissue can be constructed.

Abstract: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.

Abstract: The present invention provides a film composition containing caramel (Caramel I, II, III or IV) as a brown colorant, particularly a film composition containing a water-soluble cellulose derivative as a base component and suitably used for a capsule base, the film composition ensuring high degree of transparency because of the suppression of caramel aggregation. The present invention also provides a method for preparing the brown film composition. The present invention is enforced by adjusting pH of an aqueous solution in forming a film composition, which is obtained by solidification of an aqueous solution containing a water-soluble cellulose derivative and caramel, to a predetermined range using a pH adjuster.

Abstract: The present invention provides pharmaceutical aerosols which are useful for the prevention or treatment of infectious diseases of the airways, such as the lungs, the bronchi, or the sinunasal cavities. The aerosols comprise an active agent selected from the group of quinolone antibiotics. Also disclosed are liquid and solid compositions suitable for being converted into the aerosols, and kits comprising such compositions.

Abstract: A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. By adding a cationic polymer (in particular, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate) or a cationic polymer plus a viscous polymer to a medicine of high molecular weight for producing a preparation in powder form, it is possible to achieve effective absorption of the medicine of high molecular weight through mucosa.

Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.

Abstract: The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.

Abstract: The invention relates to a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth)acrylate copolymer, at least one water-insoluble polymer and at least one active ingredient having a solubility in demineralized water of 3.3 g/l or less, characterized in that the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property of releasing the active ingredient present in a medium buffered to pH 1.2 in dissolved form in a concentration which, after 2 hours at pH 1.2, corresponds to at least sixteen times the solubility value of the active ingredient alone at pH 1.2.

Abstract: The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided.

Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and a gelling polymer is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, or as an edible matrix, i.e., a pharmaceutical dosage form per se.

Abstract: The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components.

Abstract: A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C.

Abstract: A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered.

Abstract: An essentially dry powdered preparation containing a calcium source for the prevention and treatment of calcium deficiency conditions in mammals, e.g. dairy cows, is enclosed in a substantially water soluble, dispersible or disintegrable casing mainly composed of a cellulose material such as e.g. paperboard, cardboard, millboard, or pasteboard, or a gelatinized starch material. The calcium source is preferably a mixture of calcium chloride and calcium propionate enclosed in a cylindrical paperboard or cardboard tube or a gelatinized starch shell closed at both ends, which is administered to an animal with a bolus or bullet gun. The administration is safe and clean and the powdered mixture is quickly released in the stomach or rumen without causing erosion, irritation or inflammation of the mucosa.

Abstract: Novel cross-linked gels comprised of alkoxyetheramides grafted to polysaccharides that have superior viscosity properties have been made. By controlling the chain length of the alkoxyetheramides and the hydrophobic nature of the gel, these materials are ideal for many uses such as in hydraulic fracturing of oil-bearing geological formations, in the paint and dye industries, as dispersants, in personal care products and for carriers in controlled drug delivery.

Abstract: A hard shell capsule composition and method which is gelatin, BSE, plasticizer and preservative free, which is less sensitive to temperature, humidity and climate changes during manufacture and storage while remaining dimensionally and microbially stable.

Abstract: The invention relates to a plaster composition for administering active agents in and to bodily orifices, such as e.g. the buccal cavity, lips or genitalia.

Abstract: Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with -based materials.

Abstract: Self-dissolving needle-like or filamentous shape percutaneously absorbable preparations, by which inherently poorly absorbable drugs into the body through the skin is efficiently administered. The preparations are made of at least one material selected from the group consisting of proteins, polysaccharides, polyvinyl alcohols, carboxyvinyl polymers and sodium polyacrylic acids. An active substance contained therein is released in a sustained-release fashion (1) by forming a water-insoluble layer on its surface, (2) by holding the active substance in porous materials, or (3) by imparting a long-acting characteristic to the active substance. The present invention also provides a sheet-like carrier for holding the preparations on at least one of the sides thereof, and a piece of equipment for holding the preparations so as to facilitate the administration of them.